Tuberculosis

CD40-Stimulated Dendritic Cells Boost Immunity, But Not Disease Resistance

Published in Vaccine Weekly, April 11th, 2001

by N.R. Saltmarsh, staff medical writer - Using dendritic cells stimulated with the cytokine CD40 to vaccinate against tuberculosis enhances immune response to the disease, but does not prevent lung infection, researchers have found.

Caroline Demangel and colleagues in Australia proposed that a vaccination strategy optimizing interleukin 12 (IL-12) production by antigen-presenting cells (APCs) could stimulate immunity to TB infection.

"Since dendritic cells (DC) are the critical APC for activation of CD4⁺ and CD8⁺ T cells, we examined whether stimulation of Mycobacterium bovis bacillus Calmette-Guerin (BCG)-infected DC...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2001-04-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry